Tonix Pharmaceuticals has reported positive results from a Phase ll, dose-finding clinical trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) to treat military-related post-traumatic stress disorder (PTSD).
PTSD affects around 8.4 million Americans in any year and can develop from witnessing or experiencing a traumatic event, in which there was the severe threat or actual occurrence of grave physical harm.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Phase ll trial, AtEase Study, was a randomised, placebo-controlled study that included 231 patients with PTSD.
Conducted at 24 clinical sites in the US, the trial compared a bedtime sublingual dose of 2.8mg TNX-102 SL or 5.6mg TNX-102 SL with placebo to treat military-related PTSD.
The retention rates were reported to be 79% on TNX-102 SL 2.8mg, 84% on TNX-102 SL 5.6mg, and 73% on placebo.
The trials’ primary efficacy endpoint was the 12-week mean change from baseline in the severity of PTSD symptoms as measured by the clinician-administered PTSD Scale for DSM-5 (CAPS-5), between those treated with TNX-102 SL 2.8mg and those receiving placebo.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTonix noted that the CAPS-5 is a standardised, structured clinical interview and serves as the gold standard in research to assess the symptom severity of PTSD.
The company’s investigational drug TNX-102 SL is waiting to be approved for indication and designed to deliver cyclobenzaprine to the bloodstream rapidly through sublingual (under the tongue) absorption, as well as bypass first-pass hepatic metabolism.
As a multifunctional agent with adversary activities at the serotonin-2A, alpha-1 adrenergic, and histamine H1 receptors, TNX-102 SL is currently under clinical development to treat PTSD and is expected to provide a broad range of improvement by targeting sleep and hyperarousal.
Tonix is developing TNX-102 SL 2.8mg for daily bedtime administration to treat fibromyalgia and TNX-102 SL 5.6mg for daily bedtime administration to treat PTSD.
